- AGN 193109
-
- $62.00 / 1mg
-
2025-05-06
- CAS:171746-21-7
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
|
| | 4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid Basic information |
| Product Name: | 4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid | | Synonyms: | AGN 193109;4-[2-[5,6-Dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]benzoic Acid;CD 3106;4-((5,5-Dimethyl-8-p-tolyl-5,6-dihydronaphthalen-2-yl)ethynyl)benzoic acid;4-{[5,5-diMethyl-8-(4-Methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid;AGN 193109 SodiuM Salt;Benzoic acid, 4-[2-[5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]-;AGN193109,Autophagy,Inhibitor,Retinoic acid receptors,Retinoid X receptors,RAR/RXR,AGN 193109,AGN-193109,inhibit | | CAS: | 171746-21-7 | | MF: | C28H24O2 | | MW: | 392.49 | | EINECS: | | | Product Categories: | Aromatics Compounds;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 171746-21-7.mol | ![4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid Structure](CAS/GIF/171746-21-7.gif) |
| | 4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid Chemical Properties |
| Melting point | 246-255?C | | Boiling point | 564.5±50.0 °C(Predicted) | | density | 1.21±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | Chloroform (Slightly, Heated), DMSO (Slightly, Sonicated) | | form | Solid | | pka | 4.08±0.10(Predicted) | | color | Off-White to Pale Yellow | | Stability: | Hygroscopic |
| | 4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid Usage And Synthesis |
| Chemical Properties | Off-White Solid | | Uses | As a retinoic acid receptor (RAR) antagonist, 4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid can be used for treating chemotherapy and radiation therapy side effects. | | Biological Activity | AGN 193109 is an orally active retinoic acid receptor (RAR) antagonist th at targets all three RAR subtypes with higher affinity (RARα/β/γ Kd = 2 nM) than all-trans retinoic acid/ATRA (RARα/β/γ Kd = 9/12/19 nM). AGN 193109 potently antagonizes against ATRA-induced transcription in RARα, RARβ, and RARγ transfected CV-1 cells (by 85%, 62%, and 100%, respectively, by equal molar AGN 193109 against ATRA). AGN 193109 is also widely employeed to block RAR-mediated physiological and pathalogical processes in mice and rats in vivo via oral (1-10 mg/kg) or topical (0.3-36 μmol/kg) administration. | | in vivo | AGN 193109 (1.15 μmol/kg) does not causes overt toxicity and has no effect on spleen weight on the mice, but it suppresses TTNPB-induced increase in spleen weight of the mice. AGN 193109 also significantly reduces the cutaneous toxicity induced by ATRA. AGN 193109 (0.30 or 1.20 μmol/kg) by topical treatment significantly reduces both weight loss and cutaneous toxicity caused by oral TTNPB cotreatment[3]. | | storage | Store at -20°C |
| | 4-{[5,5-dimethyl-8-(4-methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid Preparation Products And Raw materials |
|